Cancer treatment and research communications最新文献

{"title":"Exploring the prognostic significance of vitamin D deficiency in pancreatic cancer: Disease progression and survival outcomes","authors":"Aladeen Alloubani,&nbsp;Baraa Abadalhaq,&nbsp;Amal Alshami,&nbsp;Diana Fakhory,&nbsp;Feras Abdalghani,&nbsp;Mallak Almasri,&nbsp;Maysa Alkouz","doi":"10.1016/j.ctarc.2025.100917","DOIUrl":"10.1016/j.ctarc.2025.100917","url":null,"abstract":"<div><h3>Background</h3><div>Pancreatic cancer remains one of the most aggressive malignancies with limited treatment options and poor survival rates. Vitamin D deficiency has been suggested to influence cancer progression and survival outcomes in various malignancies.</div></div><div><h3>Aim</h3><div>This study aimed to investigate the association between Vitamin D deficiency and disease progression as well as survival in patients diagnosed with pancreatic cancer.</div></div><div><h3>Methods</h3><div>A retrospective cohort study was conducted, including 151 patients diagnosed with pancreatic cancer between 2012 and 2022. Serum Vitamin D levels at the time of diagnosis were measured. Disease progression was evaluated through radiological assessments and clinical reports. Survival outcomes, including overall survival (OS) and progression-free survival (PFS), were analyzed using Kaplan-Meier survival curves and Cox proportional hazards regression models.</div></div><div><h3>Results</h3><div>Of the 151 patients, 84 (56 %) were identified as Vitamin D deficient at the time of diagnosis. The deficient group exhibited a significantly higher frequency of advanced-stage disease (stages III and IV) compared to the non-deficient group (<em>p</em> &lt; 0.05). During the follow-up period, 66 (78.6 %) of Vitamin <span>d</span>-deficient patients and 56 (84.8 %) of non-deficient patients experienced disease progression (<em>p</em> = 0.51). Moreover, Kaplan-Meier analysis showed a non-significant trend toward shorter median PFS (8.95 months vs. 9.27 months, <em>p</em> = 0.51) and OS (17.64 months vs. 19.05 months, <em>p</em> = 0.616) in the Vitamin <span>d</span>-deficient group.</div></div><div><h3>Conclusion</h3><div>Vitamin D deficiency is prevalent among patients with pancreatic cancer and appears to be associated with more advanced disease at diagnosis. Although a trend toward poorer survival outcomes was observed, the association between Vitamin D deficiency and OS/PFS did not reach statistical significance. Additional prospective studies are needed to confirm these findings and explore potential benefits of Vitamin D supplementation in pancreatic cancer management.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100917"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143821500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of upfront radiotherapy with immune checkpoint inhibitors for brain metastasis in non-small cell lung cancer","authors":"Yu Tanaka ,&nbsp;Hiroki Izumi ,&nbsp;Eri Sugiyama ,&nbsp;Tetsuya Sakai ,&nbsp;Yuji Shibata ,&nbsp;Kaname Nosaki ,&nbsp;Hibiki Udagawa ,&nbsp;Shigeki Umemura ,&nbsp;Yoshitaka Zenke ,&nbsp;Shingo Matsumoto ,&nbsp;Kiyotaka Yoh ,&nbsp;Tetsuo Akimoto ,&nbsp;Koichi Goto","doi":"10.1016/j.ctarc.2025.100937","DOIUrl":"10.1016/j.ctarc.2025.100937","url":null,"abstract":"<div><h3>Introduction</h3><div>The optimal timing of radiotherapy (RT) for asymptomatic brain metastasis (aBM) in patients with non-small cell lung cancer (NSCLC) without targetable oncogenic drivers treated with immune checkpoint inhibitors (ICIs) remains unclear. This study aimed to assess the efficacy and safety of upfront (U)-RT combined with ICIs for aBM.</div></div><div><h3>Methods</h3><div>We retrospectively reviewed consecutive patients with aBM from NSCLC who received ICI-containing chemotherapy at National Cancer Center Hospital East between 2016 and 2021. The U-RT group was defined patients who received RT for aBM before or during the first ICI cycle, and the non-U-RT group otherwise.</div></div><div><h3>Results</h3><div>Of the 324 patients with NSCLC and aBM screened, 54 were enrolled, with 34 and 20 patients in the U-RT and non-U-RT groups, respectively. The median overall survival was 27.5 and 13.8 months (hazard ratio [HR] = 0.40, 95 % confidence interval [CI] 0.19–0.87), respectively, and median cranial progression-free survival was 9.2 and 6.0 months (HR = 0.50, 95 % CI 0.25–0.98), respectively, in the U-RT and non-U-RT groups. The U-RT group showed a significantly lower aBM progression rate than the non-U-RT group (<em>P</em> = 0.04). U-RT was an independent prognostic factor in the multivariate analysis using propensity score adjustment (HR = 0.42, 95 % CI 0.18–0.96). Although severe adverse events were observed in 47 % and 35 % of patients in the U-RT and non-U-RT groups, respectively, no treatment-related deaths occurred.</div></div><div><h3>Conclusions</h3><div>ICIs with U-RT demonstrated higher efficacy with acceptable tolerability for aBM than ICIs without U-RT. Our findings should be confirmed in future prospective trials.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100937"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143935133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma biomarkers for afatinib monotherapy in EGFR-mutated non-small cell lung cancer: Novel insights from companion genomics analysis of the EXTRA study","authors":"Tomonori Makiguchi ,&nbsp;Hisashi Tanaka ,&nbsp;Kei Morikawa ,&nbsp;Aya Hirata ,&nbsp;Hidetoshi Itani ,&nbsp;Shigeru Tanzawa ,&nbsp;Kageaki Watanabe ,&nbsp;Hiroyuki Yasuda ,&nbsp;Kazuya Horiuchi ,&nbsp;Hideyuki Nakagawa ,&nbsp;Yoshitaka Seki ,&nbsp;Yoshiro Nakahara ,&nbsp;Kentaro Hayashi ,&nbsp;Nobumasa Takahashi ,&nbsp;Takeo Endo ,&nbsp;Akihiro Bessho ,&nbsp;Tetsuya Okano ,&nbsp;Kiyoshi Takeyama ,&nbsp;Akikazu Kawase ,&nbsp;Makoto Endo ,&nbsp;Nobuhiko Seki","doi":"10.1016/j.ctarc.2025.100952","DOIUrl":"10.1016/j.ctarc.2025.100952","url":null,"abstract":"<div><h3>Objectives</h3><div>Plasma-based testing with circulating cell-free DNA (cfDNA) is an active area of biomarker exploratory studies in patients with non-small cell lung cancer (NSCLC) harboring <em>EGFR</em> mutations. The Exosome-focused Translational Research for Afatinib study prospectively explored novel plasma biomarkers for afatinib monotherapy in patients with NSCLC harboring <em>EGFR</em> mutations using genomics, proteomics, epigenomics, and metabolomics. Herein, we present the results of the genomics part.</div></div><div><h3>Materials and Methods</h3><div>Clinical data of afatinib were matched with next generation sequencing (NGS)-based genomics data of cfDNA (<em>n</em> = 101) and extracellular vesicle DNA (evDNA) (<em>n</em> = 99) from pretreatment plasma samples.</div></div><div><h3>Results</h3><div>The detection sensitivity of cfDNA and evDNA mutations was 86 % (87/101) and 37 % (37/99), respectively. When cfDNA mutations were classified into tissue-matched (any <em>EGFR</em> mutations consistent with those identified in tissue) (<em>n</em> = 28), tissue-unmatched (<em>n</em> = 59), and mutation-undetected (<em>n</em> = 14) groups, cfDNA mutation status was a predictor of progression-free survival (PFS) (<em>p</em> &lt; 0.01) and overall survival (OS) (<em>p</em> &lt; 0.01). EvDNA mutation status was a predictor of OS (<em>p</em> &lt; 0.01) rather than PFS (<em>p</em> = 0.48). When the tissue-unmatched cfDNA group was subclassified into <em>EGFR</em>-related (<em>n</em> = 49) and <em>EGFR</em>-unrelated (<em>n</em> = 10) groups, the <em>EGFR</em>-unrelated group had a median PFS and 3-year OS rate of 31.2 months and 80.0 %, respectively. <em>EGFR</em>-unrelated and mutation-undetected cfDNA groups (<em>n</em> = 24) exhibited a median PFS and 3-year OS rate of &gt;30 months and &gt;80 %, respectively, with afatinib monotherapy.</div></div><div><h3>Conclusion</h3><div>This is the first large-scale prospective study of NGS-based concurrent testing for plasma cfDNA and evDNA mutations. The findings suggest that cfDNA mutation status is a promising plasma biomarker for afatinib monotherapy.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100952"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144203122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mapping the landscape of breast cancer care in Bulgaria: a scoping review","authors":"Mihaela T Dimitrova ,&nbsp;Celine Tabche","doi":"10.1016/j.ctarc.2025.100948","DOIUrl":"10.1016/j.ctarc.2025.100948","url":null,"abstract":"<div><h3>Background</h3><div>Breast cancer ranks as one of the most common cancer types in the world, and in Bulgaria, it represents a quarter of all malignant diagnoses in women. Breast cancer screening in Bulgaria is the lowest among all European Union (EU) countries. Existing literature on breast cancer care in Bulgaria is scarce. This study aims to explore the current trends, patterns, and gaps in breast cancer care in Bulgaria.</div></div><div><h3>Methods</h3><div>This study is a scoping review from peer-reviewed databases and grey literature. The results were screened against the SPIDER methodology's inclusion and exclusion criteria. Covidence was used in screening and full-text review. The study included 39 sources.</div></div><div><h3>Results</h3><div>Breast cancer is the leading cause of cancer mortality in Bulgaria and the incidence remains lower than the European average due to underreporting. Bulgaria lacks a structured breast cancer screening programme, leading to low service use, although essential prophylactic exams are covered by the National Health Insurance Fund. Barriers like the underuse of treatment and significant delays in reimbursement of new cancer therapies exist. with lower survival rates compared to the rest of the EU. While policies focus on increasing screening and improving prevention, practical steps towards achieving this have not yet been taken.</div></div><div><h3>Conclusion</h3><div>There is low screening and underreporting of breast cancer rates in Bulgaria. The lack of full reimbursement of diagnostic methods, limited adoption of the multidisciplinary approach, and complex market access processes are barriers to developing efficient treatment plans. Efficient screening and prevention are crucial for positive outcomes.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100948"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144263807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fibroblast activation protein-expression in colorectal carcinomas and implications for clinical application","authors":"Meaghan Polack ,&nbsp;Gabi W. van Pelt ,&nbsp;Augustinus S.L.P. Crobach ,&nbsp;Lioe-Fee de Geus-Oei ,&nbsp;Rob A.E.M. Tollenaar ,&nbsp;J.Han J.M. van Krieken ,&nbsp;Wilma E. Mesker","doi":"10.1016/j.ctarc.2025.100964","DOIUrl":"10.1016/j.ctarc.2025.100964","url":null,"abstract":"<div><div>Background: Colorectal cancer is highly prevalent. The stromal tumour microenvironment significantly influences tumour behaviour, and cancer-associated fibroblasts (CAFs), as major component of tumour stroma, are increasingly studied. Specifically, CAF-marker fibroblast activation protein (FAP) is gaining interest as tracer for imaging using radiolabelled FAP-inhibitor (FAPI). We describe patterns of FAP-expression, and associations to intratumoural stroma amount, establishing a biological background and potential future reference to pathology assessment.</div><div>Materials and methods: Archival histological material from 125 stage-II/III CRC patients was collected. Haematoxylin-and-eosin staining was performed to determine the tumour-stroma ratio (TSR), indicating stromal percentages in primary tumours, lymph nodes (LNs) and biopsies. On immunohistochemistry stains, FAP-expression was semiquantitatively scored as little-no, heterogeneous, or moderate-high expression. Correlation of TSR and FAP-expression with Chi-square testing was assessed. Other patterns were also described, e.g. tumour epithelial FAP-expression.</div><div>Results: In total, 93 patients (40 stage-III colon [CC], 53 stage-II/III RC) were included. Correlation between 41 (44 %) stroma-high CRC (18/40 CC, 45 %; 23/53 RC, 43 %) with high FAP-expression was not significant (<em>P</em> = 0.428 CRC; <em>P</em> = 0.470 CC; <em>P</em> = 0.615 RC). The majority of CRC had any FAP-expression (78 CRC, 84 %), mostly the invasive front, and in most associated LN metastases (87 % CRC tumour-positive LN). However, FAP-expression was often heterogeneous, even staining healthy colon and lymphoid tissue.</div><div>Conclusions: CRCs and LN metastases generally express FAP, but levels vary significantly between and within tumours and have no direct correlation with TSR. Care has to be taken translating FAPI-PET/CT results with e.g. disease extent and activity, emphasizing the importance of multidisciplinary approach.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100964"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishment and characterization of patient-derived xenograft of scrotal Paget's disease","authors":"Xiongbing Lu ,&nbsp;Ke Chen ,&nbsp;Jiaqi Mei ,&nbsp;Hua Hao ,&nbsp;Yihe Li ,&nbsp;Linxing Duan ,&nbsp;Yun Yi ,&nbsp;Yuanqiao He","doi":"10.1016/j.ctarc.2025.100967","DOIUrl":"10.1016/j.ctarc.2025.100967","url":null,"abstract":"<div><h3>Objective</h3><div>To develop a patient-derived xenograft model (PDX) of Scrotal Paget's disease (SPD), providing an experimental tool for the screening of therapeutic drugs and the development of new drugs for SPD treatment.</div></div><div><h3>Methods</h3><div>SPD tumor tissues were implanted into the subcutaneous area of the right scapula in male NOD-Scid mice to establish a PDX model. PDX tissues were characterized using H&amp;E staining, immunohistochemistry, and PCR. Cisplatin chemotherapy's antitumor effects were assessed through ex vivo histoculture drug sensitivity test (HDST) with patient tumor tissues and in vivo experiments with the PDX model.</div></div><div><h3>Results</h3><div>The patient-derived SPD tissues were tumorigenic in male NOD-Scid mice and remained stable upon serial passage. H&amp;E staining confirmed the preservation of morphological features from the patient's tumor tissues. Immunohistochemistry showed protein expression patterns consistent with clinical presentation. PCR ruled out spontaneous murine lymphoma. HDST experiments indicated cisplatin sensitivity in the patient's tumor tissues. In vivo experiments demonstrated significant tumor growth inhibition in SPD PDX mice with cisplatin, without affecting mouse body weight.</div></div><div><h3>Conclusion</h3><div>A SPD PDX model was successfully established, the PDX tumors maintained the characteristics of the patient’s original tumors.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"45 ","pages":"Article 100967"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144920317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The symptom burden of women with a known risk of breast cancer receiving risk reducing medication","authors":"Meagan S. Whisenant ,&nbsp;Jessica Treviño Jones ,&nbsp;Anneliese O. Gonzalez ,&nbsp;Therese Bartholomew Bevers ,&nbsp;Kelly Brassil ,&nbsp;Darcy A. Ponce ,&nbsp;Sharvari Kamat ,&nbsp;Emily Solis ,&nbsp;Ann Maliackal ,&nbsp;Hannah Warlick ,&nbsp;Amie Walters ,&nbsp;Chloe Denham ,&nbsp;Loretta A. Williams","doi":"10.1016/j.ctarc.2023.100784","DOIUrl":"10.1016/j.ctarc.2023.100784","url":null,"abstract":"<div><h3>Background</h3><div>For the estimated 10 million women in the United States who meet the high-risk criteria for breast cancer, evidence-based interventions may reduce the risk of breast cancer by 50–65 %. Even with substantial evidence supporting preventive medication for risk reduction, there is significant lack of uptake and adherence. The purpose of this study was to characterize the experience of women at high risk for breast cancer and define the content domain for a patient-reported outcomes (PRO) measure of symptom burden from breast cancer risk and risk reducing medication.</div></div><div><h3>Methods</h3><div>Thirty women at high risk for breast cancer and receiving risk reducing medication participated in single qualitative interviews. Content analysis was used to identify the symptom burden. An expert panel review rated the relevance of symptoms identified in the qualitative interviews to establish the items for inclusion in a PRO symptom burden measure.</div></div><div><h3>Results</h3><div>Participants had a mean age of 54.6 years; 43.3 % self-identified as Hispanic and 20.0 % self-identified as Black. Content analysis found 20 symptoms related to both risk and preventive treatment, with 8 symptoms reported by ≥ 20 % of women. All women described distress related to their risk and preventive care. Treatment-related symptoms varied based on history of risk-reducing surgery and type of endocrine therapy. Women described symptom-related interference with relationships, work, enjoyment of life, and adherence to risk reducing medication.</div></div><div><h3>Conclusions</h3><div>Women with a known high risk of breast cancer and receiving preventive care experience a unique symptom burden including multiple symptoms and functional impact related to symptoms.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100784"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139022859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genome-wide cell-free DNA methylation profiling in advanced stage ovarian cancer. Are we looking at the tumor or the patient's immune response to the tumor?","authors":"Caroline B. van den Berg ,&nbsp;Gatske M. Nieuwenhuyzen-de Boer ,&nbsp;Ingrid A. Boere ,&nbsp;Ruben G. Boers ,&nbsp;Joachim B. Boers ,&nbsp;Wilfred F.J. van-IJcken ,&nbsp;Maurice P.H.M. Jansen ,&nbsp;Tugce S. Kirmizitas ,&nbsp;Joost H. Gribnau ,&nbsp;Heleen J. van Beekhuizen","doi":"10.1016/j.ctarc.2025.100903","DOIUrl":"10.1016/j.ctarc.2025.100903","url":null,"abstract":"<div><div>The aim of this study was to identify differentially methylated regions in cell-free DNA (cfDNA) between healthy persons and patients with advanced stage ovarian cancer (ASOC) and to identify differences in cfDNA methylation before and after cytoreductive surgery. Plasma-derived cfDNA was analyzed by a high-throughput genome wide DNA methylation sequencing technique: MeD-seq. A training set of therapy naïve cfDNA samples of patients with ASOC (≥FIGO stage IIIB, n=10) was compared with cfDNA of healthy controls (n=10) to define a ASOC specific cfDNA methylation signature. A cumulative hypermethylation score was constructed and a validation set of pre- and postoperative samples of 39 patients were compared using this score. MeD-seq results of tumor tissue samples were correlated with cfDNA results. Patients with ASOC showed a clear distinct cfDNA methylation signature from healthy controls (p&lt;0.0001). This cfDNA-methylation signature resulted in preoperative hypermethylation scores (135; interquartile range 110–163) that were significantly higher than postoperative hypermethylation scores (91; interquartile range 76–101) (p&lt;0.001). The cfDNA methylation signature at baseline differed from tumor tissue and was more closely related to DNA methylation of immune-related cells (T-lymphocytes, neutrophil granulocytes, monocytes, and B-lymphocytes) than to ASOC tissue.</div><div>MeD-seq provides a promising method for genome wide methylation profiling of cfDNA. Patients with ASOC could clearly be distinguished from healthy controls and differed pre- and postoperatively.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100903"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143714721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of zanubrutinib combined with chimeric antigen receptor T-cell therapy targeting CD19 in refractory or relapsed diffuse large B cell lymphoma: A retrospective analysis","authors":"Jinhuan Xu ,&nbsp;Xiaoying Zhang ,&nbsp;Yun Li ,&nbsp;Fankai Meng ,&nbsp;Yicheng Zhang ,&nbsp;Miao Zheng","doi":"10.1016/j.ctarc.2025.100902","DOIUrl":"10.1016/j.ctarc.2025.100902","url":null,"abstract":"<div><h3>Background</h3><div>While chimeric antigen receptor T-cell (CAR T) therapy has shown promise in treating B-cell non-Hodgkin lymphoma, its efficacy is variable in patients with poor initial responses. This study investigates the efficacy and safety of zanubrutinib combined with CAR T therapy targeting CD19 in refractory/relapsed diffuse large B cell lymphoma (DLBCL).</div></div><div><h3>Methods</h3><div>We conducted a retrospective study of 17 patients with R/R DLBCL who received zanubrutinib combined with anti-CD19 CAR T-cell therapy. We assessed overall survival (OS) and progression-free survival (PFS) and conducted subgroup analyses. We also monitored CAR T-cell expansion by quantifying vector copy numbers (VCN). Safety and tolerability were assessed by documenting adverse events, including cytokine release syndrome and neurotoxicity.</div></div><div><h3>Results</h3><div>The median follow-up was 30 months (range, 4–36). The overall response rate(ORR) was 88.2 %, with 70.5 % achieving complete remission. At 24 months, the estimated PFS was 59 % (95 %CI, 40–88 %), and the OS was 71 % (95 %CI, 52–90 %). At 36 months, the estimated OS was 65 % (95 %CI, 46–92 %). Patients with non-elevated lactate dehydrogenase(LDH) levels showed a higher PFS probability (100 %) compared to those with elevated LDH (42 %, 95 %CI: 21 %-81 %) (log-rank, <em>p</em> = 0.071). The area under the receiver-operating characteristic (ROC) curve for peak CAR T-cell expansion was 0.773, suggesting an optimal cutoff at day 13 for enhancing survival (sensitivity 66.7 %, specificity 90.9 %; <em>p</em> = 0.07). Early peak expansion (before day 13) correlated with better PFS and OS (log-rank, <em>p</em> = 0.0018 and <em>p</em> = 0.0053, respectively). The total VCN AUC was 0.636, with a cutoff of 12,690 significantly predicting survival (sensitivity 83.3 %, specificity 72.7 %; <em>p</em> = 0.366). Kaplan-Meier analysis indicated statistically significant differences in OS for patients with VCN below 12,690 (log-rank, <em>p</em> = 0.017) in comparison to those exceeding 12,690, though trends in PFS did not reach statistical significance (log-rank, <em>p</em> = 0.12). Safety profiles indicated manageable cytokine release syndrome, with no severe neurotoxicity reported.</div></div><div><h3>Conclusions</h3><div>Zanubrutinib combined with CAR T-cell therapy offers an effective treatment option for patients with R/R DLBCL, enhancing response rates and survival. Detailed analysis of CAR T-cell expansion provides insight into the dynamics of cellular responses, underscoring the potential for tailored therapeutic approaches based on biological markers.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100902"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143725012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term results of a randomized controlled trial of biosimilar CT-P16 and reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer","authors":"Zoran Andric ,&nbsp;Fedor Moiseenko ,&nbsp;Tamta Makharadze ,&nbsp;Alona Oleksiienko ,&nbsp;Eduardo Yañez Ruiz ,&nbsp;SungHyun Kim ,&nbsp;KeumYoung Ahn ,&nbsp;TaeHong Park ,&nbsp;Hana Ju ,&nbsp;Eric Hyungseok Baek ,&nbsp;Soonbum Kwon ,&nbsp;IlSung Chang ,&nbsp;SinHye Kim ,&nbsp;HyunAh Kim ,&nbsp;EunKyung Lee ,&nbsp;Claire Verschraegen","doi":"10.1016/j.ctarc.2025.100970","DOIUrl":"10.1016/j.ctarc.2025.100970","url":null,"abstract":"<div><h3>Purpose</h3><div>Data from the CT-P16 3.1 study demonstrated equivalent efficacy between CT-P16, a bevacizumab biosimilar, and European-approved reference bevacizumab (EU-bevacizumab) for the primary endpoint of objective response rate (ORR) during induction treatment in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC). We now present long-term findings.</div></div><div><h3>Methods</h3><div>In this randomized, double-blind, multicenter phase 3 study, patients with metastatic or recurrent non-squamous NSCLC received CT-P16 or EU-bevacizumab (15 mg/kg every 3 weeks; ≤6 cycles) together with paclitaxel (200 mg/m²) and carboplatin (area under the curve 6.0) for 4–6 cycles during the induction period. Patients with controlled disease entered the maintenance period, continuing with CT-P16 or EU-bevacizumab as monotherapy until disease progression/intolerable toxicity. They were then followed up every 9 weeks until death or end of study. Outcomes were evaluated ≤3 years after the last patient enrollment.</div></div><div><h3>Results</h3><div>Of 689 patients receiving CT-P16 (<em>N</em> = 342) or EU-bevacizumab (<em>N</em> = 347), 499 (72.4 %) completed the induction period (CT-P16, <em>n</em> = 258 [75.4 %]; EU-bevacizumab, <em>n</em> = 241 [69.5 %]), 466 (67.6 %) initiated the maintenance period (CT-P16, <em>n</em> = 239 [69.9 %]; EU-bevacizumab, <em>n</em> = 227 [65.4 %]), and 389 (56.5 %) entered follow-up (CT-P16, <em>n</em> = 190 [55.6 %]; EU-bevacizumab, <em>n</em> = 199 [57.3 %]). Whole study ORRs were similar for CT-P16 (45.61 % [95 % confidence interval 40.34–50.89]) and EU-bevacizumab (46.11 % [95 % confidence interval 40.86–51.35]). Response duration, time to progression, progression-free survival, and overall survival were similar. No new safety signals were detected.</div></div><div><h3>Conclusions</h3><div>Long-term results of the CT-P16 3.1 study confirm equivalent efficacy of CT-P16 and EU-bevacizumab in patients with metastatic or recurrent non-squamous NSCLC.</div></div><div><h3>Trial registration number</h3><div>NCT03676192.</div></div><div><h3>Micro abstract</h3><div>Equivalent efficacy between CT-P16, a bevacizumab biosimilar, and European-approved reference bevacizumab (EU-bevacizumab) was demonstrated in a phase 3 study of patients with metastatic or recurrent non-squamous NSCLC. Long-term findings in 689 patients confirmed equivalent efficacy of CT-P16 and EU-bevacizumab; objective response rates were 45.6 % and 46.1 %, respectively. Response duration, time to progression, progression-free survival, and overall survival were also similar.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100970"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144827334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}